Cabaletta Bio and WuXi Advanced Therapies Announce Expansion

– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – –...

Related Keywords

Wuxi , Jiangsu , China , Philadelphia , Pennsylvania , United States , Gwendolyn Binder , William Gramig , David Yh Chang , Anup Marda , Manufacturing Organization , Technology Of Cabaletta , Cabaletta Bio Inc , Stern Investor Relations Inc , Exchange Commission , Nasdaq , Good Manufacturing Practice , Wuxi Advanced Therapies , Contract Testing , Chief Technology Officer , Wuxi Apptec , Cabaletta Bio , Private Securities Litigation Reform Act , Nature Medicine , Orphan Drug Designation , Fast Track Designation , Investor Relations , Markets ,